Novel and emerging therapies for B cell lymphoma

Novel and emerging therapies for B cell lymphoma

Abstract Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improved outcomes in a number of lymphoma subtypes; however, the prognosis for many patie...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Sabarish Ayyappan, Kami Maddocks
Natura:	Articolo
Lingua:	English
Pubblicazione:	BMC 2019-07-01
Serie:	Journal of Hematology & Oncology
Soggetti:	Lymphoma First in human study Immunotherapy Cellular therapy
Accesso online:	http://link.springer.com/article/10.1186/s13045-019-0752-3

Documenti analoghi

Correction to: Novel and emerging therapies for B cell lymphoma
di: Sabarish Ayyappan, et al.
Pubblicazione: (2021-02-01)

Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
di: Paulus A. F. Geerts, et al.
Pubblicazione: (2023-06-01)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
di: Alvaro J. Alencar, et al.
Pubblicazione: (2021-11-01)

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
di: Yifan Pang, et al.
Pubblicazione: (2024-04-01)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
di: Mohty R, et al.
Pubblicazione: (2023-04-01)

Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?
di: Kevin Tang, et al.
Pubblicazione: (2021-08-01)

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
di: Marco Cerrano, et al.
Pubblicazione: (2020-05-01)

Bispecific antibodies in indolent B-cell lymphomas
di: Vivek S. Radhakrishnan, et al.
Pubblicazione: (2024-01-01)

Therapy of Newly Diagnosed Follicular Lymphoma
di: Jason R. Westin, et al.
Pubblicazione: (2012-12-01)

RADIOLIGAND THERAPY IN LYMPHOMA: PAST, PRESENT AND FUTURE
di: Victor C.C.R. HERINGER, et al.
Pubblicazione: (2024-04-01)

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
di: Ya Hwee Tan, et al.
Pubblicazione: (2025-02-01)

CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
di: Semira Sheikh, et al.
Pubblicazione: (2022-08-01)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
di: Chenggong Li, et al.
Pubblicazione: (2023-01-01)

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
di: Ugo Testa, et al.
Pubblicazione: (2024-01-01)

Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma
di: Xin Wu, et al.
Pubblicazione: (2024-07-01)

Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma
di: A. M. Chekalov, et al.
Pubblicazione: (2022-11-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
di: Maria Giraudo, et al.
Pubblicazione: (2024-03-01)

Antibody Therapies for Large B-Cell Lymphoma
di: Novo M, et al.
Pubblicazione: (2021-05-01)

Editorial: Transplantation and cellular therapy in lymphomas and plasma cell disorders
di: Saad Z. Usmani, et al.
Pubblicazione: (2024-12-01)

Primary mediastinal large B cell lymphoma
di: Yating Yu, et al.
Pubblicazione: (2021-11-01)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
di: David A. Russler-Germain, et al.
Pubblicazione: (2023-07-01)

Novel target and treatment agents for natural killer/T-cell lymphoma
di: Xiao-Peng Tian, et al.
Pubblicazione: (2023-07-01)

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review
di: Andrea Rivero, et al.
Pubblicazione: (2023-05-01)

CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
di: Livio Pagano, et al.
Pubblicazione: (2009-11-01)

Born to survive: how cancer cells resist CAR T cell therapy
di: Jean Lemoine, et al.
Pubblicazione: (2021-11-01)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
di: Tingxun Lu, et al.
Pubblicazione: (2023-08-01)

The need for uniform and coordinated practices involving centrally manufactured cell therapies
di: David Stroncek, et al.
Pubblicazione: (2022-04-01)

Novel Targets and Therapies in T Cell Lymphoma
di: Murali Kesavan, et al.
Pubblicazione: (2018-12-01)

Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
di: Doris Leithner, et al.
Pubblicazione: (2024-04-01)

Cell, gene and molecular therapy : new concepts /
di: 388760 Viroj Wiwanitkit
Pubblicazione: (2009)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
di: Ugo Testa, et al.
Pubblicazione: (2023-10-01)

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas
di: Bei Hu, et al.
Pubblicazione: (2024-07-01)

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature
di: Aiqi Zhao, et al.
Pubblicazione: (2023-01-01)

Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified
di: CHEN Guangliang, WU Fangtian, CAO Junning
Pubblicazione: (2022-03-01)

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
di: Wendy W. L. Lee, et al.
Pubblicazione: (2024-04-01)

The Pharmacology of T Cell Therapies
di: Michael C. Milone, et al.
Pubblicazione: (2018-03-01)

Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH
di: Cesar Gentille, et al.
Pubblicazione: (2020-07-01)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
di: Adriana Seber, et al.
Pubblicazione: (2021-11-01)

Case report: Bridging radiation therapy before chimeric antigen receptor T-cell therapy induces sustained remission in patients with relapsed/refractory double-expressor diffuse large B-cell lymphoma with localized compressive symptoms
di: Liying Yang, et al.
Pubblicazione: (2024-09-01)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
di: Suheil Albert Atallah-Yunes, et al.
Pubblicazione: (2022-06-01)